Exploration of Potential Economics of Follow-On Biologics and Implications for Data Exclusivity Periods for Biologics
Legislative efforts to establish an abbreviated regulatory approval pathway for follow-on biologics (FOBs), also referred to as biosimilars, have generated considerable attention and debate. Legislators expect FOBs to produce cost savings through competition, much like that seen in the U.S. generic pharmaceutical market. However, biologic products, which are large complex molecules, differ from pharmaceuticals in many ways, including their basic structure, composition, and their manufacturing processes. The economics behind the establishment of an FOB market involves a plethora of issues not encountered in the generic pharmaceutical marketplace. One of the most critical and controversial issues is the determination of an appropriate period of data exclusivity or data protection for a new biologic. Building on recent research by Grabowski (2008) and using contemporary models of risk and return from the finance literature, we determine that 17 years of data exclusivity for new biologics are required. In this paper, we review some of the basic economic differences between pharmaceuticals and biologics; the potential for short run cost savings from a FOB market; and the challenging patent issues biologic products encounter that make data exclusivity periods so critical. However, the main thrust of our paper is that the considerable financial risk of biotechnology R&D, and the sensitivity of R&D to expected returns, makes it critical that Congress provide adequate incentives for biotech R&D through appropriate periods of data exclusivity or data protection for biologics
Year of publication: |
2012
|
---|---|
Authors: | Vernon, John A. |
Other Persons: | Bennett, A. (contributor) ; Golec, Joseph H. (contributor) |
Publisher: |
[2012]: [S.l.] : SSRN |
Saved in:
freely available
Extent: | 1 Online-Ressource (19 p) |
---|---|
Type of publication: | Book / Working Paper |
Language: | English |
Notes: | Nach Informationen von SSRN wurde die ursprüngliche Fassung des Dokuments May 5, 2009 erstellt |
Other identifiers: | 10.2139/ssrn.1399784 [DOI] |
Source: | ECONIS - Online Catalogue of the ZBW |
Persistent link: https://www.econbiz.de/10013117077
Saved in favorites
Similar items by person
-
Pharmaceutical price regulation : public perceptions, economic realities, and empirical evidence
Vernon, John A., (2008)
-
An exploratory study of FDA new drug review times, Prescription Drug User Fee Acts, and R&D spending
Vernon, John A., (2009)
-
Financial risk in the biotechnology industry
Golec, Joseph, (2007)
- More ...